Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in polycythemia vera and essential thrombocythemia refractory to hydroxyurea
NCT00726232Phase 2Terminated
- Sponsor
- Incyte
- Start
- Aug 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ruxolitinib in polycythemia vera (PV), essential thrombocythemia (ET), sponsored by Incyte. Started Aug 2008; status: terminated.
02
Drugs
03
Conditions
polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT00726232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726232.